Endo Pharmaceuticals Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$70.8M
Doctors Paid
24,182
Transactions
136,096
2024 Total
$603,361
Payment Breakdown by Category
Research$55.2M (78.0%)
Consulting$5.1M (7.2%)
Food & Beverage$2.7M (3.8%)
Travel$1.0M (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55.2M | 5,122 | 78.0% |
| Consulting Fee | $5.1M | 969 | 7.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.7M | 1,321 | 6.6% |
| Food and Beverage | $2.7M | 123,447 | 3.8% |
| Grant | $1.4M | 38 | 1.9% |
| Travel and Lodging | $1.0M | 3,932 | 1.4% |
| Current or prospective ownership or investment interest | $520,689 | 3 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $186,200 | 73 | 0.3% |
| Education | $69,690 | 1,185 | 0.1% |
| Charitable Contribution | $21,000 | 5 | 0.0% |
| Entertainment | $584.00 | 1 | 0.0% |
Payments by Type
Research
$55.2M
5,122 transactions
General
$15.6M
130,974 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | $10.4M | 0 | 868 |
| A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy | $5.7M | 0 | 286 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | $5.6M | 5 | 615 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | $5.0M | 30 | 421 |
| A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TREATMENT OF BUTTOCKS OR THIGH CELLULITE IN ADULT FEMALES | $3.0M | 1 | 248 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | $2.9M | 23 | 246 |
| A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | $2.8M | 3 | 647 |
| A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy | $2.6M | 0 | 101 |
| Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy Cellulite | $2.3M | 3 | 153 |
| Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single Blinded Study | $2.0M | 0 | 2 |
| A PHASE 2B, OPEN-LABEL LONG-TERM DURABILITY STUDY OF CCH FOLLOWING TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY (CELLULITE) | $1.6M | 1 | 222 |
| Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | $1.1M | 2 | 247 |
| Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronies Disease: A Randomized-Controlled Trial | $870,082 | 0 | 1 |
| A Phase 1, Open-label study to assess the safety and pharmacokinetics of a single dose of EN3835-104 1.68 mg in subjects with Edematous Fibrosclerotic Panniculopathy | $856,972 | 0 | 8 |
| A Phase 1, Open-Label, Two-Arm, Parallel-Group, Pharmacokinetic Study on Plasma Clearance of Vasopressin in Healthy Volunteers | $848,990 | 0 | 14 |
| Medical Xiaflex- Plantar Fibromatosis- POC - A Phase 1, Open-label, Randomized, Dose-ranging Study to Assess the Safety, Tolerability, and Pharmacokinetics of EN3835 in the Treatment of Plantar Fibromatosis | $798,989 | 2 | 63 |
| GRID - A Phase 2 Multicenter, Open-Label, Randomized, Parallel-Group, Multiple-Dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females | $727,762 | 2 | 42 |
| An Open Label, exploratory study evaluating the safety and different injection techniques of EN3835 for the treatment of edematous fibrosclerotic panniculopathy | $523,575 | 0 | 5 |
| A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model | $436,748 | 2 | 30 |
| A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF A SINGLE DOSE OF EN3835 3.36 MG IN SUBJECTS WITH EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | $419,298 | 0 | 4 |
| An Open-Label Study to Asses Effects of Mitigation Treatments on Bruising of CCH-Aaes Treatment of Buttock Cellulite in Adult Females--MOBI | $380,287 | 2 | 56 |
| AN OPEN-LABEL SINGLE-DOSE AND RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF OXYMORPHONE HYDROCHLORIDE HCL FOR ACUTE MODERATE TO SEVERE POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS | $309,858 | 3 | 14 |
| An Open-Label Single-Dose And Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oxymorphone Hydrochloride HCl For Acute Moderate To Severe Postoperative Pain In Pediatric Subjects | $271,340 | 3 | 35 |
| AN OPEN LABEL, EXPLORATORY STUDY EVALUATING THE SAFETY AND DIFFERENT INJECTION TECHNIQUES OF EN3835 FOR THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | $262,885 | 1 | 19 |
| Not Specific to one study | $261,846 | 6 | 57 |
| Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury | $252,867 | 0 | 2 |
| A six-month, pilot project of testosterone treatment in subjects who are undergoing Xiaflex therapy for the treatment of Peyronies disease | $217,931 | 0 | 6 |
| Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer | $208,020 | 0 | 3 |
| A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of a Single Dose of CCH 3.36 mg in Subjects With Edematous Fibrosclerotic Panniculopathy | $175,319 | 0 | 5 |
| A Phase 2a, Open Label Study to Assess the Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Females Using Photonumeric Scales, Magnetic Resonance Imaging and Histopathology | $141,800 | 0 | 9 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Sharad Mansukani, Md, MD | Ophthalmology | Moorestown, NJ | $864,829 | $0 |
| Dr. Sandra Calman, Md, MD | Family Medicine | Montara, CA | $588,938 | $0 |
| Richard Bennett, Md, MD | Urology | Royal Oak, MI | $516,884 | $0 |
| Prosper Benhaim, Md, MD | Hand Surgery | Los Angeles, CA | $443,092 | $0 |
| Robert Coats, M.d, M.D | Hand Surgery | Tinley Park, IL | $369,870 | $0 |
| Damon Adamany, Md, MD | Orthopaedic Surgery | Sun City West, AZ | $318,173 | $0 |
| Cato Laurencin, M.d, M.D | Sports Medicine | Farmington, CT | $264,103 | $0 |
| Dr. Martin Gelbard, M.d, M.D | Urology | Santa Monica, CA | $252,570 | $0 |
| Dr. Charles Laudadio, Md, MD | General Practice | Chadds Ford, PA | $243,430 | $0 |
| Dr. Culley Carson, Md, MD | Urology | Chapel Hill, NC | $238,521 | $0 |
| Gary Pess, Md, MD | Hand Surgery | Eatontown, NJ | $237,512 | $0 |
| Dr. Ashley Tapscott, D.o, D.O | Urology | Nashville, TN | $210,895 | $0 |
| L Knoll, Md, MD | Urology | Nashville, TN | $198,349 | $0 |
| Dr. James Clark, Md, MD | Internal Medicine | Charlottesville, VA | $189,493 | $0 |
| Dr. Mark Elzik, M.d, M.D | Hand Surgery | Mission Viejo, CA | $179,122 | $0 |
| Jesse Mills, Md, MD | Urology | Santa Monica, CA | $172,472 | $0 |
| Jason Fanuele, Md, MD | Orthopaedic Surgery | North Easton, MA | $168,822 | $0 |
| Sidney Jacoby, Md, MD | Orthopaedic Surgery | King Of Prussia, PA | $157,269 | $0 |
| Dr. Wayne Hellstrom, Md, MD | Urology | New Orleans, LA | $150,861 | $0 |
| Ayman Soubra, M.d, M.D | Urology | Minneapolis, MN | $143,476 | $0 |
| Dr. David Friedman, M.d, M.D | Surgery of the Hand | Weston, FL | $141,750 | $0 |
| Dr. Alexander Pastuszak, Md, Phd, MD, PHD | Surgery | Salt Lake City, UT | $123,927 | $0 |
| Peter Stein, Md, MD | Orthopaedic Surgery | Great Neck, NY | $113,540 | $0 |
| Dr. Michael Baldwin, Md, MD | Pediatric Radiology | Farmington, CT | $112,100 | $0 |
| Dr. Daniel Marrero, M.d, M.D | Diagnostic Radiology | Farmington, CT | $111,375 | $0 |
Ad
Top Products
- XIAFLEX $18.4M
- AVEED $10.8M
Associated Products (11)
Payment Categories
- Food & Beverage $2.7M
- Consulting $5.1M
- Travel & Lodging $1.0M
- Research $55.2M
About Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc. has made $70.8M in payments to 24,182 healthcare providers, recorded across 136,096 transactions in the CMS Open Payments database. In 2024, the company paid $603,361. The top product by payment volume is XIAFLEX ($18.4M).
Payments were distributed across 209 medical specialties. The top specialty by payment amount is Urology ($4.6M to 5,286 doctors).
Payment categories include: Food & Beverage ($2.7M), Consulting ($5.1M), Research ($55.2M), Travel & Lodging ($1.0M).
Endo Pharmaceuticals Inc. is associated with 11 products in the CMS Open Payments database, including XIAFLEX, AVEED, and OPANA.